Latest Hotspot

Menarini Group Highlights ORSERDU® (Elacestrant) Findings at 2024 San Antonio Breast Cancer Symposium

29 November 2024
3 min read

The Menarini Group, an international leader in pharmaceuticals and diagnostics, along with its wholly-owned subsidiary Stemline Therapeutics, Inc., dedicated to providing innovative oncology solutions for cancer patients, is set to unveil new and enhanced findings regarding ORSERDU® (elacestrant) at the forthcoming 2024 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 10-13, 2024. A key highlight will be the presentation of real-world progression-free survival (rwPFS) data for ORSERDU in adult patients diagnosed with ER+/HER2-, advanced, or metastatic breast cancer (mBC). The company will also share updated efficacy outcomes for the combination of elacestrant and abemaciclib, in addition to a comprehensive safety assessment derived from the phase 1b/2 studies of both ELECTRA and ELEVATE trials.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

ORSERDU is the first and only oral selective estrogen receptor degrader (SERD) that has been authorized for the treatment of tumors with ESR1 mutations, commonly found in up to 50% of ER+, HER2- advanced or metastatic breast cancer (mBC) cases due to previous endocrine therapy exposure in a metastatic context. Since receiving approval from the U.S. Food & Drug Administration (FDA) in January 2023, ample time has elapsed to assess the application of ORSERDU in the current landscape of mBC treatment.

Findings to be unveiled at SABCS 2024 will highlight the efficacy of ORSERDU in real-world scenarios involving patients with ER+/HER2- advanced or mBC. The data for the overall population indicated a median real-world progression-free survival (rwPFS) of 6.8 months, while patients who had received 1-2 lines of prior endocrine therapy in mBC experienced a median rwPFS of 8 months. The rwPFS observed remains consistent across various subgroups analyzed. Further updated results and additional insights regarding other patient categories will be shared during the congress.

"These promising findings demonstrate significant real-world progression-free survival with ORSERDU as a standalone treatment," stated Virginia Kaklamani, MD, DSc, a breast medical oncologist and professor at UT Health San Antonio, MD Anderson Cancer Center. "As a clinician, this data emphasizes the importance of evaluating tumors for the ESR1 mutation at each stage of disease progression through liquid biopsy, enabling us to tailor treatments effectively and enhance patient care."

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Chemical, As of November 28, 2024, there are 288 investigational drugs for the ERα target, including 53 indications, 139 R&D institutions involved, with related clinical trials reaching 149, and as many as 21485 patents.

Elacestrant hydrochloride is a small molecule drug designed to target ERα, and it is used to treat various therapeutic areas including neoplasms, skin and musculoskeletal diseases, nervous system diseases, and digestive system disorders. 

图形用户界面, 文本, 应用程序

描述已自动生成

Innovent's SINTBILO® and New Olverembatinib Indication Added to China's National Drug List
Latest Hotspot
4 min read
Innovent's SINTBILO® and New Olverembatinib Indication Added to China's National Drug List
29 November 2024
Innovent has announced that SINTBILO® is being included for the first time in China’s National Reimbursement Drug List, along with a new indication for Olverembatinib.
Read →
Akeso's Cadonilimab and Ivonescimab Added to China's Reimbursed Drug List
Latest Hotspot
4 min read
Akeso's Cadonilimab and Ivonescimab Added to China's Reimbursed Drug List
29 November 2024
Akeso has announced that Cadonilimab and Ivonescimab are now part of China's national list for reimbursed drugs.
Read →
LEQEMBI®: New Alzheimer's Treatment Launched in South Korea
Latest Hotspot
3 min read
LEQEMBI®: New Alzheimer's Treatment Launched in South Korea
29 November 2024
Lecanemab, marketed as LEQEMBI®, has been introduced for Alzheimer's disease treatment in South Korea.
Read →
Kelun-Biotech's Sac-TMT Approved in China for Advanced Metastatic TNBC Treatment
Latest Hotspot
3 min read
Kelun-Biotech's Sac-TMT Approved in China for Advanced Metastatic TNBC Treatment
29 November 2024
Kelun-Biotech's TROP2 ADC, sacituzumab tirumotecan (sac-TMT), has received marketing authorization from China's NMPA for the treatment of second-line or later advanced metastatic TNBC.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.